Pharmacokinetics of cefonicid in serum and its penetration into lung tissue, bronchial mucosa and pleura. 1989

G Furlan, and G Besa, and G Broccali, and A Gusmitta
Division of Thoracic and Cardiovascular Surgery, Hospital Centre Borgo Trento, Verona, Italy.

Cefonicid pharmacokinetics in serum and tissue penetration into the lung parenchyma, bronchial mucosa and pleura were studied in 39 patients undergoing lung excision for malignancy. Cefonicid concentrations in serum and tissues samples were assayed at different times after a single 1 g intramuscular administration. The concentrations observed were much higher than the reported minimal inhibitory concentrations for the microorganisms commonly responsible for bronchial and pulmonary infections and therapeutic concentrations were still detectable in the tissues 24 h after dosing. Kinetic findings demonstrated a similar half-life for cefonicid in tissues and in serum. These data provided a further kinetic explanation for the observed clinical efficacy of cefonicid with a single daily dose.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010994 Pleura The thin serous membrane enveloping the lungs (LUNG) and lining the THORACIC CAVITY. Pleura consist of two layers, the inner visceral pleura lying next to the pulmonary parenchyma and the outer parietal pleura. Between the two layers is the PLEURAL CAVITY which contains a thin film of liquid. Parietal Pleura,Visceral Pleura,Pleura, Parietal,Pleura, Visceral
D001980 Bronchi The larger air passages of the lungs arising from the terminal bifurcation of the TRACHEA. They include the largest two primary bronchi which branch out into secondary bronchi, and tertiary bronchi which extend into BRONCHIOLES and PULMONARY ALVEOLI. Primary Bronchi,Primary Bronchus,Secondary Bronchi,Secondary Bronchus,Tertiary Bronchi,Tertiary Bronchus,Bronchi, Primary,Bronchi, Secondary,Bronchi, Tertiary,Bronchus,Bronchus, Primary,Bronchus, Secondary,Bronchus, Tertiary
D002435 Cefamandole Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate. Cephamandole,Compound 83405
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G Furlan, and G Besa, and G Broccali, and A Gusmitta
February 1988, The Journal of antimicrobial chemotherapy,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
February 1991, Journal of chemotherapy (Florence, Italy),
G Furlan, and G Besa, and G Broccali, and A Gusmitta
January 1990, Chemotherapy,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
January 1993, European journal of clinical pharmacology,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
November 1984, Thorax,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
December 1986, The American review of respiratory disease,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
August 1988, The Journal of antimicrobial chemotherapy,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
October 1981, Thorax,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
January 1984, Reviews of infectious diseases,
G Furlan, and G Besa, and G Broccali, and A Gusmitta
August 1987, British journal of clinical pharmacology,
Copied contents to your clipboard!